Can You Still Get Ozempic for Weight Loss?

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic demand for weight loss has strained pharmaceutical supply chains, leaving many patients unable to fill prescriptions at traditional pharmacies. PlexusDx connects you with licensed 503A compounding pharmacies that prepare pharmaceutical-grade semaglutide injections, ensuring consistent access to this proven weight loss medication without insurance requirements or membership fees.

Why Ozempic Supply Has Become Limited for Weight Loss

Ozempic (semaglutide) was originally approved by the FDA for type 2 diabetes management. When clinical data showed significant weight loss benefits in non-diabetic patients, demand surged beyond manufacturing capacity. Novo Nordisk, the sole manufacturer of brand-name Ozempic, has faced ongoing supply constraints as healthcare providers and patients compete for limited inventory.

Insurance coverage decisions further complicate access. Many plans limit semaglutide to diabetes treatment, leaving weight loss patients to pay out-of-pocket or remain on waitlists. Some pharmacies have enacted rationing policies, prioritizing diabetic patients and restricting quantities for weight management use. This created a gap in the market that compounding pharmacies now fill with identical active pharmaceutical ingredients.

The gap between demand and supply has persisted for over two years, affecting millions of patients. Industry analysts expect brand-name shortages to continue as obesity treatment adoption expands globally. This reality has prompted both patients and providers to explore legitimate, regulated alternatives that bypass traditional pharmacy bottlenecks.

How Compounded Semaglutide Differs from Brand Ozempic

Compounded semaglutide uses the same active pharmaceutical ingredient as Ozempic but is prepared in licensed 503A compounding pharmacies under strict federal oversight. The FDA does not pre-approve individual compounded medications, but it regulates the pharmacies that prepare them. PlexusDx partners exclusively with licensed 503A compounders—never 503B facilities, which handle larger-scale manufacturing and are intended for sterile products only.

Brand Ozempic comes in prefilled, auto-injector pens with fixed dosing intervals. Compounded semaglutide is typically prepared in vials at your prescribed dose, offering flexibility in dose adjustments as your treatment progresses. Both formulations deliver semaglutide through subcutaneous injection once weekly, targeting the same GLP-1 receptor pathways that reduce appetite and improve metabolic control.

Quality standards for 503A compounded medications include ingredient verification, sterility testing, and potency assurance. PlexusDx vets all partner pharmacies for state licensure, quality certifications, and clean compliance records. This transparency ensures you receive a reliably prepared product without the supply uncertainty that plagues brand-name channels.

Access and Affordability Without Insurance Requirements

PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with no insurance requirement, membership fee, or hidden charges. Your dose may need to go up as your treatment progresses—your price won't. This flat-rate model eliminates the cost surprises that arise from insurance denials or formulary changes. Payments are HSA and FSA eligible, allowing you to use pre-tax healthcare dollars toward your treatment.

Accessing treatment through PlexusDx requires no prior authorization, insurance appeals, or pharmacy network limitations. You complete an initial health screening with a licensed provider, receive a personalized treatment plan, and have prescriptions filled directly by a compounding partner. The entire process is streamlined for patients who need reliable, immediate access to semaglutide for weight loss.

Many patients save money compared to brand Ozempic copays or uninsured out-of-pocket costs, which can exceed $900 monthly. PlexusDx serves all 50 states, removing geographic barriers that limit compounding pharmacy access in some regions. This accessibility model has opened weight loss treatment to patients previously unable to navigate traditional supply and insurance constraints.

Genetic Insights for Personalized Semaglutide Response

Not every patient responds identically to semaglutide, and genetic variations influence how effectively your body processes the medication. The PlexusDx Precision Peptide Genetic Test identifies genetic variants in key weight-regulation pathways, including the GIPR rs1800437 variants that directly impact semaglutide responsiveness. This $298 test maps 14 peptide pathways, 49 individual peptides, and 150+ genetic insights specific to your metabolism.

The PlexusDx Precision Peptide Genetic Test reports on variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as safe as brand Ozempic?

Compounded semaglutide contains the identical active pharmaceutical ingredient as Ozempic and is prepared under FDA-regulated 503A pharmacy standards. Safety depends on pharmacy quality controls, which PlexusDx verifies before partnership. Both formulations work through the same GLP-1 receptor mechanism. Report any side effects to your PlexusDx provider immediately, as they can adjust your dose or recommend alternative compounds.

How long does it take to see weight loss results with semaglutide?

Clinical trials show measurable weight loss begins within 4–8 weeks of starting semaglutide, with continued progress over 12–16 weeks as doses are titrated. Most patients lose 10–15% of body weight within 6 months at therapeutic doses. Your PlexusDx provider will monitor your progress and adjust your treatment plan based on your individual response and genetic predispositions.

Do I need insurance to start semaglutide at PlexusDx?

No. PlexusDx requires no insurance, membership fee, or prior authorization. Compounded semaglutide is $189 per month month-to-month, or from $149/mo on the 6-month plan and is HSA/FSA eligible. You pay a flat rate regardless of dose, so price increases don't occur as your treatment advances. PlexusDx serves all 50 states with direct access to licensed compounding pharmacies.

What are the most common side effects of semaglutide?

Nausea, vomiting, constipation, and reduced appetite are the most frequently reported side effects, particularly during the first 2–4 weeks. These effects typically decrease as your body adapts. Serious side effects are rare but can include pancreatitis or severe allergic reactions. Your PlexusDx provider screens for contraindications and monitors your response throughout treatment.

How does the PlexusDx Precision Peptide Genetic Test improve my results?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.